Congratulations: Beilu Pharma's Iohexol Injection Passed the Consistency Evaluation for Generic Drugs

2021/04/21

Iohexol Contrast

Recently, Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA) on Iohexol Injection (100ml:35g, 100ml:30g), and the company's iohexol contrast passed the quality and efficacy consistency evaluation for generic drugs！

PREV : Congratulations: Beilu Pharma's Iodixanol Injection Passed the Consistency Evaluation for Generic Drugs

NEXT : Good News: Beilu Pharmaceutical won the 2020 National Adverse Drug Reactions Monitoring and Evaluation Excellent Unit

References

Related Products

Iohexol Injection

Iopamidol Injection

Iodixanol Injection

Related Beilu News

Beilu Pharma's Dyclonine Hydrochloride Chemical Active Pharmaceutical Ingredient (API) Approved by NMPA
May 14, 2026Recently, Beilu Pharma received the "Notification of Approval for Marketing Application of Chemical API" for Dyclonine Hydrochloride approved and issued by the National Medical Products Admi...view
Gadobutrol Injection Proposed for Selection in the 11th National Drug Centralized Procurement
October 30, 2025Recently, Beijing Beilu Pharmaceutical Co., Ltd. participated in the bidding work for the eleventh batch of national drug centralized procurement organized by Chinese National Organization for Drug Pr...view
Introduction of Intravenous Contrast Media
December 27, 20211. The concept of intravenous contrast mediaThere are many types of contrast medium in the clinic, and different types of contrast medium will produce different feelings after they are injected into p...view
What is the Contrast Material? How Does It Work?
July 5, 2022Ⅰ. What is the contrast material?Contrastive material is used to improve the contrast of the images produced by X-rays, computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound, allo...view
[New Product] Beilu Pharma's Mupirocin Ointment Granted NMPA Approval
May 9, 2026Recently, Beilu Pharma received the Drug Registration Certificate for Mupirocin Ointment, approved and issued by the National Medical Products Administration (NMPA).Developed by GlaxoSmithKline (GSK),...view
Beilu Pharmaceutical's 2024 Annual Online Performance Presentation on May 9
May 9, 2025To facilitate a more in-depth and comprehensive understanding of the Company among a broad base of investors, the Company is scheduled to hold its 2024 Annual Online Performance Presentation on Friday...view